Many patients with BRAF-altered pediatric low-grade glioma stayed off therapy after planned tovorafenib cessation in the 4-year FIREFLY-1 update.
News|Videos|October 9, 2025
Pivotal ARROS-1 Efficacy and Safety Data: Zidesamtinib in TKI Pretreated Patients With Advanced/Metastatic ROS1+ NSCLC
Author(s)Ross Camidge, MD, PhD
Ross Camidge, MD, PhD, discusses a pivotal phase 2/3 clinical trial (ARROS-1) evaluating the efficacy and safety of zidesamtinib in patients with advanced or metastatic ROS1-positive non–small cell lung cancer (NSCLC) who have previously received tyrosine kinase inhibitor (TKI) therapy.
Advertisement
Advertisement
Related to this article
Sarah Goldberg, MD, MPH, details how clinicians can choose among frontline regimens, act on resistance mechanisms, and incorporate ADCs and newer agents across the spectrum of EGFR-mutated NSCLC.
The FDA approved pimicotinib for tenosynovial giant cell tumor, accepted a gedatolisib filing in advanced breast cancer, and more.
Serial amino acid PET flagged responses earlier than MRI in IDH-mutant glioma treated with vorasidenib, interim data show.
Longer mirdametinib treatment increased confirmed and deep responses as treatment-related adverse effects declined in neurofibromatosis type 1 tumors.
Patrick Forde, MD, MBBCh, details how chemoimmunotherapy, pathologic response, and targeted therapy are reshaping resectable NSCLC care.
Long-term data show that plixorafenib yielded durable responses and no cumulative adverse effects in BRAF-altered primary central nervous system tumors.
The FDA approved durvalumab plus enfortumab vedotin for cisplatin-ineligible muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
Dr Johnson on Immune Activation With Indoximod-Based Chemo-Immunotherapy in Recurrent Ependymoma
2
Tovorafenib Sustains Treatment-Free Intervals in R/R BRAF-Altered Pediatric Low-Grade Glioma
3
Dr Miller on Whole Genome Sequencing of CSF ctDNA in High-Grade Glioma
4
Vorasidenib Elicits Early Metabolic Responses in IDH-Mutant Glioma
5